Bicara Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 382.74K shares, a 1312.16% increase year-over-year.
- Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 366.42K shares, a 311.88% increase year-over-year.
- Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 384.25K shares, a 1545.39% increase year-over-year.
- Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 56.40K shares.
- Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 556.71K shares, a 33.64% increase from fiscal 2024.
- Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 416.57K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 382.74K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 1.19M shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 366.42K shares 10-Q · filed 2026-05-11 | 834.16K shares derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | 384.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 556.71K shares 10-K · filed 2026-03-30 |
| 2025-09-30 | 56.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 195.82K shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 27.10K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | |
| 2025-03-31 | 88.96K shares 10-Q · filed 2025-05-13 | |
| 2024-12-31 | 23.35K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 416.57K shares 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |